Sandoz Files Application For Biosimilar To Amgen's Enbrel
The U.S. Food and Drug Administration has accepted Sandoz Inc.'s application for a proposed biosimilar to Amgen Inc.'s biologic arthritis drug Enbrel, the company announced on Friday, about a month after...To view the full article, register now.
Already a subscriber? Click here to view full article